Marker Therapeutics Sells Subsidiary to Lenders
Ticker: MRKR · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $75.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-reduction, divestiture, restructuring
TL;DR
Marker Therapeutics selling its subsidiary to lenders to cut debt.
AI Summary
Marker Therapeutics, Inc. announced on June 6, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics LLC, to a newly formed entity controlled by its existing lenders. This transaction is expected to significantly reduce Marker Therapeutics, Inc.'s outstanding debt.
Why It Matters
This sale aims to deleverage the company's balance sheet by reducing outstanding debt, which could improve its financial standing and operational flexibility.
Risk Assessment
Risk Level: medium — The transaction involves a sale to existing lenders, which may indicate financial distress and carries inherent risks associated with debt restructuring.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- Marker Therapeutics LLC (company) — Wholly-owned subsidiary being sold
- June 6, 2024 (date) — Date of the definitive agreement
FAQ
What is the primary purpose of selling Marker Therapeutics LLC?
The primary purpose is to significantly reduce Marker Therapeutics, Inc.'s outstanding debt through a definitive agreement to sell its wholly-owned subsidiary.
Who is acquiring Marker Therapeutics LLC?
Marker Therapeutics LLC is being acquired by a newly formed entity controlled by Marker Therapeutics, Inc.'s existing lenders.
When was the definitive agreement for the sale entered into?
The definitive agreement was entered into on June 6, 2024.
What is the relationship between Marker Therapeutics, Inc. and Marker Therapeutics LLC?
Marker Therapeutics LLC is a wholly-owned subsidiary of Marker Therapeutics, Inc.
What is the expected financial impact of this transaction on Marker Therapeutics, Inc.?
The transaction is expected to significantly reduce Marker Therapeutics, Inc.'s outstanding debt.
Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-12 16:05:47
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
- $75.0 million — ng an aggregate offering price of up to $75.0 million. (the "ATM Offering Program"). The Comp
Filing Documents
- tm2416968d1_8k.htm (8-K) — 35KB
- 0001104659-24-070830.txt ( ) — 205KB
- mrkr-20240606.xsd (EX-101.SCH) — 3KB
- mrkr-20240606_lab.xml (EX-101.LAB) — 33KB
- mrkr-20240606_pre.xml (EX-101.PRE) — 22KB
- tm2416968d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 6, 2024, Marker Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024. Of the 8,913,490 shares outstanding as of the record date, 5,646,313 shares, or 63.35%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1 : Election of five nominees to serve as directors until the 2025 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 3,038,468 183,932 Steven Elms 3,068,548 153,852 John Wilson 3,040,976 181,424 Juan Vera 3,068,257 154,143 Katharine Knobil 3,063,767 158,633 Broker Non-Votes: 2,423,913. All nominees were elected. Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company's named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 2,931,920 276,480 14,000 Broker Non-Votes: 2,423,913. Proposal No. 3 : Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Marcum LLP 5,137,819 494,128 14,366 Broker Non-Votes: 0.
01
Item 8.01 Other Events. On June 10, 2024, the Company provided notice of its termination of that certain Controlled Equity Offering SM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which the Company could offer and sell, from time to time at its discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. (the "ATM Offering Program"). The Company is not subject to any termination penalties related to the termination of the ATM Agreement.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: June 11, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer